Skip to content

BridgeBio Pharma

US · BBIO #1254 by market cap Listed 2019
66.50 -0.46 -0.69%
Live - 5344 symbols - heartbeat 198s ago · 2026-10-08 05:32
Pre-market 66.30 -0.30%
After-hours 65.99 -0.77%
Overnight 66.50 0.00%
Market cap
13.00B
P/B
-5.17
EPS
-3.78
Reader sentiment Are you bullish or bearish on BBIO?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $120
    Market Newswire · 2026/7/13
  • Rating change
    Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $111
    Market Newswire · 2026/8/3
  • Rating change
    William Blair Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
    Market Newswire · 2026/8/3
  • Rating change
    Jefferies Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $100
    Market Newswire · 2026/7/6
  • Rating change
    Citi Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Raises Target Price to $93
    Market Newswire · 2026/7/16
  • Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $115
    Market Newswire · 2026/8/31
  • Rating change
    Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $96
    Market Newswire · 2026/6/22
  • TD Cowen Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $110
    Market Newswire · 2026/9/24
  • Rating change
    Citi Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Maintains Target Price $93
    Market Newswire · 2026/7/17
  • Rating change
    A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $94 to $115
    Market Newswire · 2026/8/12
  • Rating change
    A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $110 to $157
    Market Newswire · 2026/9/1
  • Barclays Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $157
    Market Newswire · 2026/9/30
  • BridgeBio (BBIO.US) cardiac therapy acoramidis outperforms Pfizer’s (PFE.US) competitor drug in real-world study
    Zhitong Finance · 2026/9/24
  • Rating change
    A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $97 to $115
    Market Newswire · 2026/8/11
  • Rating change
    H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $120
    Market Newswire · 2026/9/10
  • Rating change
    A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $94 to $157
    Market Newswire · 2026/8/13
  • Rating change
    RBC Capital Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $100
    Market Newswire · 2026/8/14
  • Evercore Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $130
    Market Newswire · 2026/9/14
  • Rating change
    BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $101
    Market Newswire · 2026/7/22
  • Rating change
    Analysts Are Bullish on These Healthcare Stocks: Sagimet Biosciences, Inc. Class A (SGMT), BridgeBio Pharma (BBIO)
    TipRanks · 2026/8/12

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 05:32:13 · For reference only, not investment advice and not tailored to your situation.